Trace amine associated receptor 1 and movement control

Parkinsonism and Related Disorders

Volumn 14, Issue SUPPL.2, 2008, Pages

  Sotnikova, Tatyana D ^a   Zorina, Olesya I ^a   Ghisi, Valentina ^a   Caron, Marc G ^a   Gainetdinov, Raul R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Amphetamine; Dopamine; L dopa; TAAR1; Trace amine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 6 HYDROXY 3,4 METHYLENEDIOXYAMPHETAMINE; AMFEBUTAMONE; AMINE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTIPARKINSON AGENT; CHLORAMPHETAMINE; DEXAMPHETAMINE; DOPAMINE; FENFLURAMINE; LEVODOPA; METHAMPHETAMINE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; PHENTERMINE; RECEPTOR; TRACE AMINE ASSOCIATED RECEPTOR 1;

AKINESIA; ARTICLE; DOPAMINE DEFICIENT MOUSE; KNOCKOUT MOUSE; MONOAMINE NERVE CELL; MOVEMENT (PHYSIOLOGY); NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RIGIDITY;

ANIMALS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MICE; MICE, KNOCKOUT; MOVEMENT; RECEPTORS, G-PROTEIN-COUPLED;

EID: 47049100558     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.04.006     Document Type: Article

References (24)

1. Hornykiewicz O. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent. Amino Acids 23 (2002) 65-70
2. Carlsson A. Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problems. J Neural Transm 109 (2002) 777-787
3. Misu Y., Goshima Y., Ueda H., and Okamura H. Neurobiology of L-DOPAergic systems. Prog Neurobiol 49 (1996) 415-454
4. Premont R.T., Gainetdinov R.R., and Caron M.G. Following the trace of elusive amines. Proc Natl Acad Sci U S A 98 (2001) 9474-9475
5. Branchek T.A., and Blackburn T.P. Trace amine receptors as targets for novel therapeutics: legend, myth and fact. Curr Opin Pharmacol 3 (2003) 90-97
6. Berry M.D. Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem 90 (2004) 257-271
7. Sotnikova T.D., Budygin E.A., Jones S.R., Dykstra L.A., Caron M.G., and Gainetdinov R.R. Dopamine transporter-dependent and -independent actions of trace amine beta-phenylethylamine. J Neurochem 91 (2004) 362-373
8. Borowsky B., Adham N., Jones K.A., Raddatz R., Artymyshyn R., Ogozalek K.L., et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci U S A 98 (2001) 8966-8971
9. Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60 (2001) 1181-1188
10. Lindemann L., and Hoener M.C. A renaissance in trace amines inspired by a novel GPCR family. Trends Pharmacol Sci 26 (2005) 274-281
11. Grandy D.K. Trace amine-associated receptor 1-family archetype or iconoclast?. Pharmacol Ther 116 (2007) 355-390
12. Gainetdinov R.R., and Caron M.G. Monoamine transporters: from genes to behavior. Annu Rev Pharmacol Toxicol 43 (2003) 261-284
13. Jones S.R., Gainetdinov R.R., Jaber M., Giros B., Wightman R.M., and Caron M.G. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci U S A 95 (1998) 4029-4034
14. Sotnikova T.D., Beaulieu J.M., Barak L.S., Wetsel W.C., Caron M.G., and Gainetdinov R.R. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol 3 (2005) e271
15. Sotnikova T.D., Caron M.G., and Gainetdinov R.R. DDD mice, a novel acute mouse model of Parkinson's disease. Neurology 67 7 Suppl. 2 (2006) S12-S17
16. Wolinsky T.D., Swanson C.J., Smith K.E., Zhong H., Borowsky B., Seeman P., et al. The trace amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 6 (2006) 628-639
17. Miller G.M., Verrico C.D., Jassen A., Konar M., Yang H., Panas H., et al. Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther 313 (2005) 983-994
18. Scanlan T.S., Suchland K.L., Hart M.E., Chiellini G., Huang Y., Kruzich P.J., et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 10 (2004) 638-642
19. Lundblad M., Picconi B., Lindgren H., and Cenci M.A. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 16 (2004) 110-123
20. Giros B., Jaber M., Jones S.R., Wightman R.M., and Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379 (1996) 606-612
21. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., and Caron M.G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283 (1999) 397-401
22. Xie Z., and Miller G.M. Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther 321 (2007) 128-136
23. Xie Z., Westmoreland S.V., Bahn M.E., Chen G.L., Yang H., Vallender E.J., et al. Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther 321 (2007) 116-127
24. Mercuri N.B., and Bernardi G. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?. Trends Pharmacol Sci 26 (2005) 341-344